

Influenza Vaccines Available for the 2015-16 Season for Vaccines for Children Providers in Oklahoma by Age Group and Name of the Vaccine in OSIS

The names of the vaccines in OSIS are based on the age group that can receive the vaccine and the funding source used for the purchase of the vaccine.

Influenza Vaccines Available through the VFC Program (VFC influenza vaccines include some of the same vaccines that may be purchased privately and used for all persons and ages for which they are licensed. Vaccines purchased for the VFC program may be given only to VFC-eligible children age 18 years and younger. The names of these vaccines include the 'VFC' extension in OSIS for the purpose of tracking VFC vaccine usage.)

Brand Name	Manufacturer	Presentation	Mercury Content ¹ (mcg. per 0.5 mL dose)	Ages Eligible for this Vaccine	Route	Name in OSIS
FluMist ² (Quadrivalent)	MedImmune	0.2 mL single dose sprayer	0.0	2 yrs. - 18 yrs.	IN	FLUMIST – VFC QD
Fluzone (Quadrivalent)	Sanofi Pasteur	0.25 mL single-dose syringe	0.0	6 mos.- 35 mos.	IM	FLUZONE 6-35M-VFC-QD
		5.0 mL multi-dose vial	25 mcg.	6 mos. - 18 yrs.	IM	FLUZONE 6M-18Y-VFCQD
Fluarix (Quadrivalent)	GlaxoSmithKline	0.5 mL single-dose syringe	0.0	3 yrs. - 18 yrs.	IM	FLUARIX 3Y-18Y-VFC QD

Additional Influenza Vaccines Licensed for Use in the U.S. for the 2015-16 Season NOT supplied by the Vaccines for Children Program

Brand Name	Manufacturer	Presentation	Mercury Content ¹ (mcg. per 0.5 mL dose)	Ages Eligible for this Vaccine	Route	Name in OSIS
FluMist ² (Quadrivalent)	MedImmune	0.2 mL single dose sprayer	0.0	2 yrs. - 49yrs.	IN	FLUMIST QD
FluLaval (Quadrivalent)	ID Biomedical ⁴	5.0 mL 10 dose vial	<25 mcg.	≥3 yrs.	IM	FLULAVAL 3Y & UP QD
Fluarix (Quadrivalent)	GlaxoSmithKline	0.5 mL single-dose syringe	0.0	≥3 yrs	IM	FLUARIX 3Y AND UP QD
Fluvirin (Trivalent)	Novartis	5.0 mL multi-dose vial	25.0 mcg.	≥4 yrs.	IM	FLUVIRIN 4Y & UP
		0.5 mL single-dose syringe, 10 pack	≤1 mcg.			
Afluria ⁴ (Trivalent)	bioCSL, previously CSL Biotherapies ⁵	0.5 mL single-dose pre-filled syringe	0	≥9 yrs.	IM	FLUAFLURIA 9Y AND UP
		5.0 mL multi-dose vial	24.5	≥9 yrs.	IM	FLUAFLURIA 9Y AND UP
Flublok ⁶ (Trivalent)	Protein Sciences	0.5 mL single-dose vial	0	≥18 yrs.	IM	No name assigned
Flucelvax (Trivalent)	Novartis	0.5 mL single-dose syringe	0	≥18 yrs.	IM	FLUCELVAX 18Y AND UP

Brand Name	Manufacturer	Presentation	Mercury Content ¹ (mcg. per 0.5 mL dose)	Ages Eligible for this Vaccine	Route	Name in OSIS
Fluzone (Trivalent)	Sanofi Pasteur	5.0 mL multi-dose vial	25 mcg.	≥6 mos.	IM	FLUZONE 6M AND UP
Fluzone High Dose (Trivalent)		0.5 mL single-dose syringe	0	≥65 yrs.	IM	FLUZONE 65Y & UP
Fluzone Intradermal (Quadrivalent)	Sanofi Pasteur	0.1 mL prefilled microinjection system (gray plunger rod)	0	18 through 64 yrs.	ID	FLUZONE ID
Fluzone (Quadrivalent)		0.25 mL single-dose prefilled syringe (yellow plunger rod)		6 mos. - 35 mos.	IM	FLUZONE 6-35M QD
		0.5 mL single-dose prefilled syringe (purple plunger rod)		≥36 mos. or 3 yrs.		FLUZONE 3Y AND UP QD
		0.5 mL single-dose vial		≥36 mos. or 3 yrs.		FLUZONE 3Y AND UP QD

¹Mercury as a component of thimerosal (a preservative used in multi-dose vials)

²FluMist is indicated for healthy, non-pregnant persons aged 2 through 49 years. Health care providers should consult the medical record, when available, to identify children aged 2 through 4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged 2 through 4 years should be asked, "In the past 12 months, has a health care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and children who have asthma or who had a wheezing episode noted in the medical record within the past 12 months should not receive FluMist. Persons who care for severely immunosuppressed persons who require a protective environment should not receive FluMist given the theoretical risk for transmission of the live attenuated vaccine virus.

³Distributed by GlaxoSmithKline

⁴The Afluria age indication per the package insert is ≥5 years; however, the Advisory Committee on Immunization Practices recommends that Afluria not be used in children aged 6 months through 8 years because of increased risk of febrile reactions noted in this age group with CSL's 2010 Southern Hemisphere Afluria. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5 through 8 years who has a medical condition that increases the child's risk for influenza complications, Afluria can be used; however, vaccination providers should discuss with the parents or caregivers the benefits and risks of influenza vaccinations with Afluria before administering the vaccine. Afluria may be used in persons aged ≥9 years.

⁵Distributed by Merck

⁶Flublok, (Trivalent) is an option for adults age 18 through 49 who have an egg allergy, regardless of severity.

Notes:

- Children aged 6 months through 8 years require 2 doses of influenza vaccine (administered ≥4 weeks apart) during their first season of vaccination to optimize response.
- Children aged 6 months through 8 years who have previously received 2 or more doses of trivalent or quadrivalent influenza vaccine before July 1, 2015 require only one dose for the 2015-16 season. The 2 previous doses need not have been given during the same or consecutive seasons.
- For adults and older children, the recommended site for intramuscular influenza vaccination is the deltoid muscle.
- The preferred site for infants and young children is the anterolateral aspect of the thigh.

Resources:

- Screening checklist for contraindications to live attenuated influenza vaccine (LAIV), FluMist: <http://www.immunize.org/catg.d/p4067.pdf>
- Screening checklist for contraindications to inactivated injectable influenza vaccine (IIV): <http://www.immunize.org/catg.d/p4066.pdf>